Mª A Vaz Salgado1, M Soto2, Mª E Reguero3, G Muñoz4, A Cabañero4, I Gallego5, S Resano5, F Longo6, A Madariaga6, A Gomez6, A Carrato6. 1. Medical Oncology Department, Ramón y Cajal University Hospital, Carretera de Colmenar Km 9,100, 28034, Madrid, Spain. mavaz4@gmail.com. 2. Medical Oncology Department, Hospital General de Segovia, Segovia, Spain. 3. Pathlogy Department, Ramón y Cajal University Hospital, Madrid, Spain. 4. Thoraric Surgery Department, Ramón y Cajal University Hospital, Madrid, Spain. 5. Radiology Department, Ramón y Cajal University Hospital, Madrid, Spain. 6. Medical Oncology Department, Ramón y Cajal University Hospital, Carretera de Colmenar Km 9,100, 28034, Madrid, Spain.
Abstract
BACKGROUND: Solitary fibrous tumors (SFTs) are a rare type of soft tissue sarcoma of unpredictable clinical behavior. Some clinicopathologic characteristics have also been related to patient outcome. METHODS: This study is a retrospective review of 30 patients. We analyzed the clinical course and pathological factors to predict recurrence. RESULTS: The mean age was 55.9 years. Forty-five percent were located in the thoracic region. The mean tumor size was 10 cm (max24). Thirty-three percent had a relapse and 20 % have died. Median time to relapse was 7.18 (1-13) years. Median overall survival (OS) was 15.5 years (0-32). On histopathologic analysis, 6 % percent had >4 mitoses, 23 % had necroses, and 36 % had atypia/pleomorphism. Forty-three percent had tumor size >10 cm. Forty-six percent had at least one characteristic of malignancy. None of this data could predict clinical behavior by itself. CONCLUSIONS: SFT can be an aggressive disease and relapses can occur several years from diagnosis. We did not find any clinicopathologic factors that could predict the tumor behavior accurately. Nevertheless, it should be consider that we included different tumor locations and the sample size is small.
BACKGROUND: Solitary fibrous tumors (SFTs) are a rare type of soft tissue sarcoma of unpredictable clinical behavior. Some clinicopathologic characteristics have also been related to patient outcome. METHODS: This study is a retrospective review of 30 patients. We analyzed the clinical course and pathological factors to predict recurrence. RESULTS: The mean age was 55.9 years. Forty-five percent were located in the thoracic region. The mean tumor size was 10 cm (max24). Thirty-three percent had a relapse and 20 % have died. Median time to relapse was 7.18 (1-13) years. Median overall survival (OS) was 15.5 years (0-32). On histopathologic analysis, 6 % percent had >4 mitoses, 23 % had necroses, and 36 % had atypia/pleomorphism. Forty-three percent had tumor size >10 cm. Forty-six percent had at least one characteristic of malignancy. None of this data could predict clinical behavior by itself. CONCLUSIONS: SFT can be an aggressive disease and relapses can occur several years from diagnosis. We did not find any clinicopathologic factors that could predict the tumor behavior accurately. Nevertheless, it should be consider that we included different tumor locations and the sample size is small.
Authors: O Rena; P L Filosso; E Papalia; M Molinatti; P Di Marzio; G Maggi; A Oliaro Journal: Eur J Cardiothorac Surg Date: 2001-02 Impact factor: 4.191
Authors: A Oliaro; P L Filosso; C Casadio; E Ruffini; R Cianci; C Porrello; M Molinatti; A Cavallo; F Pischedda; M Rizzo Journal: Minerva Chir Date: 1994-12 Impact factor: 1.000
Authors: Tatiana Georgiesh; Ninna Aggerholm-Pedersen; Patrick Schöffski; Yifan Zhang; Andrea Napolitano; Judith V M G Bovée; Åse Hjelle; Gordon Tang; Mateusz Spalek; Margherita Nannini; David Swanson; Thomas Baad-Hansen; Raf Sciot; Asle C Hesla; Paul Huang; Desiree Dorleijn; Hans Kristian Haugland; Maribel Lacambra; Jacek Skoczylas; Maria A Pantaleo; Rick L Haas; Leonardo A Meza-Zepeda; Florian Haller; Anna M Czarnecka; Herbert Loong; Nina L Jebsen; Michiel van de Sande; Robin L Jones; Felix Haglund; Iris Timmermans; Akmal Safwat; Bodil Bjerkehagen; Kjetil Boye Journal: Br J Cancer Date: 2022-08-27 Impact factor: 9.075
Authors: Rick L Haas; Iris Walraven; Estelle Lecointe-Artzner; Winan J van Houdt; Dirk Strauss; Yvonne Schrage; Andrew J Hayes; Chandrajit P Raut; Mark Fairweather; Elizabeth H Baldini; Alessandro Gronchi; Laura De Rosa; Anthony M Griffin; Peter C Ferguson; Jay Wunder; Michiel A J van de Sande; Augustinus D G Krol; Jacus Skoczylas; Claudia Sangalli; Silvia Stacchiotti Journal: Cancer Date: 2020-04-21 Impact factor: 6.860